Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41189   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2013-000685-11
    Sponsor's Protocol Code Number:PR-30-5011-C
    National Competent Authority:Sweden - MPA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-08-02
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSweden - MPA
    A.2EudraCT number2013-000685-11
    A.3Full title of the trial
    A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
    A.4.1Sponsor's protocol code numberPR-30-5011-C
    A.5.4Other Identifiers
    Name:IND No.Number:100,996
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTESARO Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTESARO Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTESARO Inc.
    B.5.2Functional name of contact pointClinical Trial Mailbox
    B.5.3 Address:
    B.5.3.1Street Address1000 Winter Street, Suite 3300
    B.5.3.2Town/ cityWaltham
    B.5.3.3Post code02451
    B.5.3.4CountryUnited States
    B.5.4Telephone number0017812572536
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNiraparib (GSK 3985771)
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNiraparib
    D.3.9.1CAS number 1038915-60-4
    D.3.9.2Current sponsor codeL-001946812-005R, L-001946812 and MK-4827
    D.3.9.3Other descriptive nameNIRAPARIB
    D.3.9.4EV Substance CodeSUB93448
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Platinum Sensitive Ovarian Cancer
    E.1.1.1Medical condition in easily understood language
    Platinum Sensitive Ovarian Cancer
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10033128
    E.1.2Term Ovarian cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression-free survival (PFS).
    E.2.2Secondary objectives of the trial
    (1) concordance of a candidate companion BRACanalysis diagnostic test compared to the centralized BRCA mutation test used in this study, if needed;
    (2) Concordance of a candidate companion HRD diagnostic test compared to the HRD test used in this study, if needed;
    (3) to evaluate additional measures of clinical benefit including patient reported outcomes (PROs), time to first subsequent treatment (TFST), time to second subsequent treatment (TSST), time from treatment randomization to the earlier date of assessment of progression on the next anticancer therapy following study treatment or death by any cause (progression-free survival 2; PFS2), chemotherapy-free interval (CFI), and overall survival (OS);
    (4) to evaluate the safety and tolerability of niraparib compared to placebo in the indicated target population;
    (5) to evaluate QTc in a subset of niraparib-treated ovarian cancer patients
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Food effect substudy, Version 1.0, date 03-May-2013
    Objective: To assess the effect of a high fat meal on the pharmacokinetics of a single 300 mg dose
    of niraparib in patients with ovarian cancer.
    E.3Principal inclusion criteria
    1. Female, age at least 18 years
    2. Patient agrees to undergo analysis of their gBRCA status. (Testing must be completed prior to randomization. The sample may be submitted at any time prior to the screening period if it appears patient is likely to meet other eligibility requirements. To facilitate early testing, a separate informed consent form [ICF] specific for genotyping will be available to
    be signed prior to gBRCA status testing.)
    3. Histologically diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
    4. High grade (or Grade 3) serous or high grade predominantly serous histology or known to have gBRCAmut
    5. Patients must have completed at least 2 previous courses of platinum- containing therapy (eg, carboplatin, oxaliplatin, or cisplatin):
    a. For the penultimate (next to last) platinum-based chemotherapy course prior to enrollment on the study:
    i. A patient must have platinum sensitive disease after this treatment; defined as achieving a response (CR or PR) and disease progression > 6 months after completion of their last dose of platinum therapy (document 6-12 months or > 12 months). (Source documentation required and may include physician or clinic notes.)
    b. For the last chemotherapy course prior to being randomized in the
    i. Patients must have received a platinum-containing regimen for a minimum of 4 cycles
    ii. Patients must have achieved a partial or complete tumor response
    iii. Following the last regimen, patients must have either
    1. CA-125 in the normal range OR
    2. CA-125 decrease by more than 90% during their last platinum regimen which is stable for at least 7 days (ie, no increase > 15%) iv. Following the last regimen, patients must not have any measurable lesion > 2 cm at the time of study entry
    c. Patients must be randomized within 8 weeks after completion of their final dose of the platinum-containing regimen.
    Note: The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteria
    6. The patient agrees to complete PROs during study treatment and at 1 additional time point 8 weeks following study treatment discontinuation. It is estimated that completion of PROs will take less than 20 minutes at each time point. Since these are questionnaires, their completion will not interfere with, or preclude, future treatment or clinical studies
    7. Formalin fixed, paraffin-embedded archival tumor available from the primary or recurrent cancer required for all patients
    8. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
    9. Adequate organ function
    a. Absolute neutrophil count (ANC) ≥ 1,500/μL
    b. Platelets ≥ 100,000/μL
    c. Hemoglobin ≥ 9 g/dL
    d. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation
    e. Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ 1 x ULN
    f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
    10. Able to take oral medications
    11. Women of childbearing potential must use adequate birth control for the duration of study participation

    Additional Inclusion Criteria for Food Effect Sub-Study
    With the exception of inclusion criteria 2, 4, 5, 6, 7, and 8 (above), all main study inclusion criteria apply. In addition, the following inclusion criteria apply to the FE sub-study only:
    1. Entry criteria are broadened to include patients with ovarian cancer regardless of platinum sensitivity and burden of disease as long as no standard therapy exists or the patient has refused standard therapy.
    2. ECOG 0-2
    3. Must be able to eat a high fat meal and fast for 12 hours

    E.4Principal exclusion criteria
    1. Drainage of ascites during last 2 cycles of last chemotherapy
    2. Palliative radiotherapy within 1 week encompassing > 20% of the bone marrow
    3. Persistent > Grade 2 toxicity from prior cancer therapy
    4. Symptomatic uncontrolled brain or leptomeningeal metastases. (To be considered "controlled", central nervous system (CNS) disease must have undergone treatment [eg, radiation or chemotherapy] at least 1 month prior to study entry. The patient must not have any new or progressive signs or symptoms related to the CNS disease and must be taking a stable dose of steroids or no steroids.) A scan to confirm the absence of brainmetastases is not required. Patients with spinal cord
    compression may be considered if they have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days.
    5. Known hypersensitivity to the components of niraparib
    6. Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
    7. Diagnosis, detection or treatment of invasive cancer other than ovarian cancer ≤ 2 years prior to randomization (except basal or squamous cell carcinoma of the skin that has been definitively treated)
    8. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression,
    superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
    9. History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study treatment, or is not in the best interest of the patient to participate
    • Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment
    10. Patient is pregnant or breast feeding, or expecting to conceive children within the projected duration of the study treatment
    11. Immunocompromised patients (Note: patients with splenectomy are allowed.)
    12. Patients with known active hepatic disease (ie, Hepatitis B or C)
    13. Prior treatment with a known PARP inhibitor
    14. Patients with a baseline QT prolongation > 470 milliseconds
    15. Patients are receiving concomitant medications that prolong QTc and are unable to discontinue use for the duration of the study

    Additional Exclusion Criteria for Food Effect Sub-Study:
    With the exception of exclusion criteria 1 and 13 (above), all main study exclusion criteria apply. In addition, the following exclusion criteria apply to the FE sub-study only:
    1. Chemotherapy within 3 weeks of study start
    2. Patient taking a proton pump inhibitor, antacids, or H2 blocker within 48 hours of dose
    E.5 End points
    E.5.1Primary end point(s)
    Progression-Free Survival
    E.5.1.1Timepoint(s) of evaluation of this end point
    Date of first documentation of objective progression or death by any cause in the absence of
    documented objective progression whichever occurs first.
    E.5.2Secondary end point(s)
    1. Concordance of a candidate companion BRACanalysis diagnostic test compared to the centralized BRCA mutation test used in this study, if needed
    2. Concordance of a candidate companion HRD diagnostic test compared to the HRD test used in this study, if needed
    3. Observed changes from baseline in the following PROs:
    a. FOSI
    b. EQ-5D-5L
    c. Neuropathy questionnaire
    4. Outcomes for the next anticancer therapy following study treatment (best response, dose limiting toxicities, and date of progression) will be collected using source documentation.
    5. PFS2 is defined as the time from treatment randomization to the earlier date of assessment of progression on the next anticancer therapy following study treatment or death by any cause. Determination of progression will be by site physician clinical and radiographic assessment (clinic and radiology notes may serve as source documentation).
    6. Time to first subsequent therapy (TFST) is defined as the date of randomization in the current study to the start date of the first subsequent anticancer therapy.
    7. Time to second subsequent therapy (TSST) is defined as the date of randomization in the current study to the start date of the second subsequent anticancer therapy.
    8. Chemotherapy-free interval (CFI) the time from last platinum dose until initiation of next anticancer therapy (excluding maintenance therapy). CFI relative to CFI from prior chemotherapy regimens will be evaluated (clinic notes may serve as source documentation).
    9. OS as measured from the date of randomization to the date of death by any cause
    10. Time to CA-125 progression from time of randomization
    11. Evaluation of the effects of food on the PK of niraparib
    E.5.2.1Timepoint(s) of evaluation of this end point
    Per Protocol
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    (1) Concordance of a candidate companion BRACanalysis diagnostic test compared to the centralized BRCA mutation test used in this study, if needed
    (2) Concordance of a candidate companion HRD diagnostic test compared to the HRD test used in this study, if needed
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA66
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years8
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years8
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 272
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 218
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 343
    F.4.2.2In the whole clinical trial 490
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Follow up according to protocol (see section 3 and 7)
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation ENGOT Consortium
    G.4.3.4Network Country Denmark
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-09-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-09-03
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice